Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

 
• By Jessica Merrill
  
text 10 percentages discount 3d red white banner, letters and block, business concept
Truxima will launch at a 10% lower WAC than Rituxan • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from New Products

More from Scrip